Synopsis: Six pharma and pharma-linked stocks are on analysts’ radar with upside potential of up to 26%, backed by improving fundamentals, recovery in key markets, and strong domestic and export growth prospects despite near-term volatility and sector-specific...
Synopsis: Brokerage maintains a Buy with a ₹690 target, implying 35% upside from ₹510.65. EBITDA margin guidance raised to 17–18% by FY28, backed by ₹700 crore capex and backward integration. The luxury portfolio is expected to double from ₹40 crore to ₹80 crore,...
Synopsis: While small-cap stocks often stay under the radar, some fundamentally strong companies with zero debt are currently trading at steep discounts. These debt-free stocks enjoy financial stability, efficient capital usage, and strong long-term growth potential,...
Synopsis:- A brokerage has given a ‘Buy’ call with a Rs 230 target, implying 52% upside from Rs 151.20. Q3FY26 saw a 3% YoY decline and margins compressed to 9%. Despite short-term pressure, a 140-molecule pipeline, 47% US market share, and a strategic...
Synopsis: Morgan Stanley stays bullish on IGI, citing the AGL acquisition’s US expansion, coloured gemstone diversification, strong cash backing, and long-term revenue growth visibility, implying ~52% upside to its target. This Small-cap stock, engaged in...
Synopsis: Zensar Technologies shares are in focus after Motilal Oswal believes that the company still has significant potential to rally 52% upside from current levels, citing improved margins, significant deal wins worth $180 million and more, supporting the...
Synopsis:- The defence PSU remains in focus after broker upgrades, with target prices raised to Rs 565, implying 28% upside. Strong Q3 performance, 30% operating margins, 71% achievement of FY26 order inflow targets, and a solid Rs 73,015 crore order book continue...
